You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾生物-B(06185.HK)澄清新型疫苗三期臨床試驗尚未入組
阿思達克 08-18 12:09
康希諾生物-B(06185.HK)公布,注意到公司股票價格波動,以及部分媒體有關重組新型冠狀病毒疫苗(腺病毒載體)(「Ad5-nCoV」)進展的報道。

康希諾作出澄清及聲明,公司於今年8月11日收到「一種以人複製缺陷腺病毒為載體的重組新型冠狀病毒疫苗」的授予發明專利權通知書。該專利由中國人民解放軍軍事科學院軍事醫學研究院與公司聯合申請;及Ad5-nCoV的二期臨床試驗已完成。公司目前正在與多個國家聯繫,計劃儘快推動Ad5-nCoV國際多中心三期臨床試驗。截至目前,Ad5-nCoV的三期臨床試驗尚未入組。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account